{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:07:27Z","timestamp":1648559247101},"reference-count":5,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med","J. Jpn. Soc. Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/naika.104.508","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T17:06:46Z","timestamp":1457543206000},"page":"508-512","source":"Crossref","is-referenced-by-count":0,"title":["6. Advances in Basic Research and Therapy of Multiple Sclerosis"],"prefix":"10.2169","volume":"104","author":[{"given":"Takashi","family":"Yamamura","sequence":"first","affiliation":[{"name":"Department of Immunology, National Institute of Neuroscience, NCNP"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Weiner HL: The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 65: 239-248, 2009.","DOI":"10.1002\/ana.21640"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Sawcer S, et al: Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219, 2011.","DOI":"10.1038\/nature10251"},{"key":"3","doi-asserted-by":"crossref","unstructured":"4) Yamamura T, Miyake S: Diet, gut flora, and multiple sclerosis: current research and future perspectives. Multiple Sclerosis Immunology, Springer, Germany, 2013, 115-126.","DOI":"10.1007\/978-1-4614-7953-6_6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"6) Chihara N, et al: Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108: 3701-3706, 2011.","DOI":"10.1073\/pnas.1017385108"},{"key":"5","doi-asserted-by":"crossref","unstructured":"8) Araki M, et al: Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82: 1302-1306, 2014.","DOI":"10.1212\/WNL.0000000000000317"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":["6\uff0e\u591a\u767a\u6027\u786c\u5316\u75c7\u306e\u75c5\u614b\u7814\u7a76\u3068\u6cbb\u7642\u306e\u9032\u6b69"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/104\/3\/104_508\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T07:05:21Z","timestamp":1567667121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/104\/3\/104_508\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.104.508","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}